ABIVAX Stock: Shares Gain 22% Over the Week in a Declining Paris Market
ABIVAX stock closed on Friday at €122.00, marking a weekly increase of 22%. This rise is part of an exceptional annual performance of 1630%. While the CAC 40 fell by 0.59% and the SBF 120 by 0.43% over the same period, the French biotech's stock continues to stand out.
Weekly Performance Overview
Over the past week, from December 18 to 24, ABIVAX stock showed a sustained upward trajectory. On December 18, it closed at €97.60, before rising to €100.00 on December 19, then jumping to €115.40 on December 22 with an increase of 15.40%. On December 23, the price reached €119.80, up 3.81%, and finished at €122.00 on December 24 with an additional gain of 1.84%. This weekly variation of 22% sharply contrasts with the declines of the main Paris indices: the CAC 40 lost 0.59% and the SBF 120 0.43% over the same period. In the longer term, the one-year performance has reached 1630%, bringing the price well beyond its annual lows around €4.51. The stock is now trading at a high level, with a three-month price target set at €118.00 by analysts. Eligible for the PEA-PME, ABIVAX benefits from increased visibility in the markets, in a context where its market capitalization reflects a marked growth dynamic since the beginning of 2025. Trading has been intense, highlighting interest in this value within the biotech sector. This week's rise is based on a solid foundation, with the price having already increased by more than 1600% since January, according to historical data. The slight downturn in the Paris market highlights the resilience of the stock against general trends.
Significant Events and Market Speculation
On December 22, ABIVAX surged by more than 15% during the session, closing at €115.40 at the top of the SBF 120. This surge coincided with the biotech's entry into the Nasdaq Biotechnology Index in New York, a key milestone for its international visibility. Driven by the clinical successes of its candidate obefazimod in the treatment of ulcerative colitis, the stock fueled speculation. On December 24, a takeover rumor by Eli Lilly, an American pharmaceutical giant, propelled the price by more than 9% to about €115 during the session, before closing at €122.00 at the end of the week. This potential market of $30 billion by 2030 for the treatment of inflammatory bowel diseases enhances the company's attractiveness. Convincing clinical results have contributed to this speculative dynamic, in a sector where few biotechs show such progressions. December 23 saw a consolidation with a moderate rise, before the final acceleration. These recent developments partly explain the weekly vigor, despite the lack of official confirmation on the rumors.
Technical Analysis and Stock Performance
Technically, the price of €122.00 is at the resistance level, with a support threshold at €89.40. The monthly volatility stands at 25.39, while the very low beta of 0.02 indicates a low correlation with the general market. The stock is trading above its 50-day moving average (€96.07) and well above its 200-day moving average (€47.43). The MACD indicator shows a line at 4.10, the RSI is at 70, and the Bollinger Bands place the upper at €122.87 and the lower at €87.46. These technical levels reflect a bullish dynamic over the short and medium terms.
